ABBV-166

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameABBV-166
Drug Alias NameSkyrizi/LutikizumabABBV-166
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionInterleukin-23 subunit p19 inhibitorsInterleukin-1 alpha inhibitorsInterleukin-1 beta inhibitors
TargetsInterleukin-23 subunit p19Interleukin-1 alphaInterleukin-1 beta
Therapy Area/IndicationsCrohn DiseaseArthritis, Psoriatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[6] 
CombinationsYes RisankizumabLutikizumab
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseArthritis, Psoriatic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A